211 related articles for article (PubMed ID: 6302550)
1. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.
Wachtel H
Neuropharmacology; 1983 Mar; 22(3):267-72. PubMed ID: 6302550
[TBL] [Abstract][Full Text] [Related]
2. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors.
Wachtel H; Schneider HH
Neuropharmacology; 1986 Oct; 25(10):1119-26. PubMed ID: 2946976
[TBL] [Abstract][Full Text] [Related]
3. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors.
Wachtel H
Psychopharmacology (Berl); 1982; 77(4):309-16. PubMed ID: 6182575
[TBL] [Abstract][Full Text] [Related]
4. Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors.
Wachtel H
J Neural Transm; 1983; 56(2-3):139-52. PubMed ID: 6190991
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant properties of some phosphodiesterase inhibitors.
Przegaliński E; Bigajska K
Pol J Pharmacol Pharm; 1983; 35(3):233-40. PubMed ID: 6194518
[TBL] [Abstract][Full Text] [Related]
6. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo.
Wachtel H
J Pharm Pharmacol; 1983 Jul; 35(7):440-4. PubMed ID: 6136585
[TBL] [Abstract][Full Text] [Related]
7. Effects of forskolin and cyclic nucleotides in animal models predictive of antidepressant activity: interactions with rolipram.
Wachtel H; Löschmann PA
Psychopharmacology (Berl); 1986; 90(4):430-5. PubMed ID: 3027733
[TBL] [Abstract][Full Text] [Related]
8. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Nov; 16(5):796-803. PubMed ID: 1703603
[TBL] [Abstract][Full Text] [Related]
9. Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors.
Griebel G; Misslin R; Vogel E; Bourguignon JJ
Pharmacol Biochem Behav; 1991 Jun; 39(2):321-3. PubMed ID: 1658815
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate.
O'Donnell JM
J Pharmacol Exp Ther; 1993 Mar; 264(3):1168-78. PubMed ID: 8383740
[TBL] [Abstract][Full Text] [Related]
11. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats.
Itoh T; Tokumura M; Abe K
Eur J Pharmacol; 2004 Sep; 498(1-3):135-42. PubMed ID: 15363987
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.
Marivet MC; Bourguignon JJ; Lugnier C; Mann A; Stoclet JC; Wermuth CG
J Med Chem; 1989 Jul; 32(7):1450-7. PubMed ID: 2544722
[TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
14. The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration.
Knapp CM; Foye MM; Ciraulo DA; Kornetsky C
Pharmacol Biochem Behav; 1999 Jan; 62(1):151-8. PubMed ID: 9972858
[TBL] [Abstract][Full Text] [Related]
15. The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Gordeladze JO
Biosci Rep; 1990 Aug; 10(4):375-88. PubMed ID: 2174276
[TBL] [Abstract][Full Text] [Related]
16. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
17. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
[TBL] [Abstract][Full Text] [Related]
18. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase.
Schmiechen R; Schneider HH; Wachtel H
Psychopharmacology (Berl); 1990; 102(1):17-20. PubMed ID: 2392503
[TBL] [Abstract][Full Text] [Related]
19. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram.
Kochetkova M; Burns FM; Souness JE
Biochem Pharmacol; 1995 Dec; 50(12):2033-8. PubMed ID: 8849330
[TBL] [Abstract][Full Text] [Related]
20. Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.
Turner NC; Lamb J; Worby A; Murray KJ
Br J Pharmacol; 1994 Apr; 111(4):1047-52. PubMed ID: 8032589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
